Published in Healthcare Finance, Tax and Law Weekly, February 14th, 2007
Higgins succeeds Henry F. Blissenbach who has served as chairman and interim CEO since August 2006.
Blissenbach will continue as chairman of the board of directors.
Higgins brings to Ligand over 14 years of corporate development, financing, strategic planning, commercialization, and investment banking experience in the biopharmaceutical industry. Prior to joining Ligand, Higgins was CFO, executive vice president, finance, administration, and corporate development of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.